Malignant melanomas are frequently characterized by elevated levels of wild-type p53, suggesting that p53 function could be suppressed by a mechanism different from p53 mutation. We analysed the functionality of the p53-signaling pathway in a panel of seven human melanoma cell lines consisting of one p53-deficient line, two lines with mutant p53, and four lines expressing wildtype p53. Only lines with wild-type p53 were characterized by elevated levels of endogenous p21, high activity of p53-responsive reporters and accumulation of p53 in response to genotoxic stress, common properties of functional p53. The presence of wild-type p53 was associated with depletion or loss of p14 ARF and p16 expression. The levels of p33
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, two major products of Ing1 locus and putative coregulators of p53, were elevated in all cell lines tested; however, ectopic expression of either ING1 isoform had no effect on cell proliferation. All lines retained expression of Apaf-1, and all but one remained sensitive to ectopic expression of retrovirus-transduced p53. Our data indicate that regardless of abnormally high levels of p53 in melanomas, their p53 remains competent in transactivation of its targets, and, if highly overexpressed, capable of growth inhibition. Hence, the p53 pathway in malignant melanomas can be considered for pharmacological targeting and anticancer gene therapy. Oncogene (2003 Oncogene ( ) 22, 4911-4917. doi:10.1038 Keywords: melanoma; p53; Ing1; tumor suppressor; transactivation Malignant melanoma is a highly aggressive type of cancer with a propensity to early metastasis and no effective treatment in its more advanced stages. The problem is further aggravated by a steady rise in the incidence of the disease during the last few decades (ACS, 2002) . However, understanding underlying mechanisms of this disease and the development of effective therapeutic strategies is hindered by insufficient knowledge about the molecular alterations that underline the development of this malignancy.
In order to gain an insight into the genesis of melanoma, we investigated the p53 pathway, which is arguably the most common target of oncogenic lesions across a broad spectrum of malignancies. p53 encodes a nuclear transcriptional factor that mediates negative regulation of cell growth in response to a variety of stress stimuli (reviewed in Vogelstein et al. (2000) ). The function of p53 is critically important for cancer prevention and p53 deficiency at organismal level is associated with a high frequency of cancer development in mice and men (Donehower et al., 1992; Birch et al., 1998) .
In the tumors, p53 is most commonly inactivated by missense mutations within the highly conserved DNAbinding domain of p53 (Hollstein et al., 1991) . p53 function can be also abrogated via binding to MDM2 (Haupt et al., 1997) or to viral proteins such as SV40 large T antigen, adenoviral E1B and HPV E6 (Mietz et al., 1992; Yew and Berk, 1992) . Upon certain stimuli such as activation of oncogenes, MDM-2 binding to p53 could be abrogated by one of the products of the INK4a locus, p14 ARF (Zhang et al., 1998) . Transactivation by p53 has been shown to depend on cooperation with a putative tumor suppressor ING1, and an antisense fragment of ING1 interferes with p53 functions (Garkavtsev et al., 1998) . It has been also proposed that ING1 contributes to p53 stability by interfering with MDM2 function (Leung et al., 2002) . In addition, function of p53 can be abrogated by alteration of its subcellular localization so that p53 is sequestered in the cytoplasm (Moll et al., 1996) .
Earlier studies of melanoma have revealed elevated levels of p53 with a predominantly nuclear localization of the protein (Yamamoto and Takahashi, 1993; Montano et al., 1994; Rauth et al., 1994b; Loggini et al., 2001; Rass et al., 2001) . As opposed to other types of cancer, mutations in the p53 gene are rare in melanomas (Albino et al., 1994; Montano et al., 1994; Ragnarsson-Olding et al., 2002; Soengas et al., 2001) . Nevertheless, as judged from the malignant nature of melanoma, wild-type p53 in this tumor obviously fails to function as a tumor suppressor. Markedly abnormal karyotype, different among the melanoma cell lines but never diploid (Rauth et al., 1994a) , is also consistent with chromosomal instability so typical for the p53-deficient cells (Yin et al., 1992) . The role of p14 ARF , which is involved in p53 regulation (Zhang et al., 1998) , is not clear since mutations in Ink4a locus, which are strongly linked to the development of melanoma affect the function of both products, p16 and 14 ARF . There is also no evidence of any viral proteins implicated in the etiology of melanomas. Reported loss of expression of Apaf-1 (Soengas et al., 2001) , an important component of intrinsic apoptotic machinery, may account for the failure of the cytotoxic, but not cytostatic function of p53 in these tumors. There are recent reports of altered levels and rare mutations of ING1 protein in melanomas (Campos et al., 2002; Nouman et al., 2002) ; however, the functional significance of this observation remains unclear.
In the current study, we analysed the structural and functional status of p53 in seven human melanoma cell lines 7, 8, 11, 16, 23 and 29) (Rauth et al., 1994a, b) and in UISO-CMN-1 cells derived from benign naevus (Mehta et al., 2002; Salti et al., 2001) . Structural alterations in p53 were previously reported, albeit at a low frequency, in human melanoma (Bae et al., 1996; Soengas et al., 2001) . Sequencing of p53 cDNA showed that UISO-CMN-1 and UISO-MEL-7, 8, 16 and 29 had wild-type p53. A common polymorphism at codon 72 (Matlashewski et al., 1987) was found in UISO-CMN-1, UISO-MEL-7, 16, 23 and 29. In contradiction to a previous report of Rauth et al. (1994b) , we found that UISO-MEL-11 contained nucleotide transition of T to C in the second position of codon 195 resulting in substitution of isoleucine for threonine in exon 6 within the DNA-binding domain of p53 protein ( Figure 1a ). Although this mutation does not affect 'hot spot' codons and has not been previously described in melanomas, it is not uncommon in other malignancies. In fact, it accounts for more than 6% of the p53 mutations found in uterine cancers (Olivier et al., 2002) . UISO-MEL-23 had an internal deletion of codons 178-183 in exon 5 of the p53 gene ( Figure 1b ). Although this mutation does not cause a frameshift, it affects the DNA-binding domain of the protein, disrupting the third conserved region including the histidine residue that coordinates the essential Zn atom (Soussi and Beroud, 2001) . The deletion removes the region between short direct repeats, possibly pointing to a recombinational error or a slippage event during replication. Sequencing histograms of p53 from UISO-MEL-23 and 11 show no superimposition of a wild-type sequence on top of the mutant one ( Figure 1 ). This suggests a typical case of loss of heterozygocity that commonly accompanies the acquisition of p53 mutations in other cancers (Gallion et al., 1995; Bigner et al., 1999; Wistuba et al., 2001; Sunamura et al., 2002) .
The steady-state levels of p53 in 6, 7, 8, 11, 16 and 23 and normal diploid fibroblasts WS1 were assessed by Western blotting (Figure 2a ). p53-was undetectable in p53 -deficient UISO-MEL-6 as well as fibroblasts WS1 reflecting a short half-life of noninduced p53 in normal cells (Mora et al., 1982) . In accordance with a previous immunocytochemical study (Rauth et al., 1994b) , UISO-MEL-29 demonstrated low, while 8, 11, 16 and 23 showed high levels of p53 protein. While abundant p53 in UISO-MEL-11 and 23 was in line with the earlier reports of increased accumulation of tumor-derived mutant p53 (Kastan et al., 1992) , high levels of wild-type p53 in the nucleus of UISO-MEL-3, 7, 8 and 16 were unexpected and prompted us to investigate the functional status of the protein.
We examined whether endogenous wild-type p53 is capable of accumulation in response to genotoxic stress. The expression of p53 protein was compared before and after gamma irradiation. A marked increase in the level of p53 was observed both in the cells with high (UISO-MEL-7, Figure 2c ) and low (UISO-MEL-29, Figure 2d ) basal levels of p53. This observation suggests that abnormally high levels of wild-type p53 protein in melanoma cannot be attributed to altered protein stability and that these cells contain factors required for p53 activation in response to genotoxic stress.
To investigate the functionality of p53 in melanoma cell lines, we first determined the steady-state levels of a well-known p53 transcriptional target, p21
Waf (el-Deiry et al., 1993) . As shown in Figure 2a , UISO-MEL-6, 11 and 23, which carry inactivated p53, maintained low levels of p21
Waf1 . These levels were comparable to that of noninduced control fibroblasts WS1 and, probably, reflected p53-independent basal expression of p21 Waf1 . In contrast, all the cell lines with wild-type p53 (UISO-MEL-7, 8, 16 and 29) contained significantly higher levels of p21
Waf1 suggesting that their p53 is not only functional but is also constitutively active.
To test this assumption, we assayed the ability of endogenous p53 in melanoma cell lines to activate transcription of p53-responsive reporter constructs PG 13 -CAT (Kern et al., 1991) (Figure 3a ) and p21-CAT (Garkavtsev et al., 1998) (Figure 3b ) in transient transfection assays. UISO-MEL-7, 8, 16 and 29 showed 4-30-fold p53-dependent induction of both reporters. In contrast, cell lines UISO-MEL-11 and 23 that carry mutations in the p53 gene failed to stimulate a reporter indicating that these mutations abrogate the p53 transactivating ability. As expected, UISO-MEL-6, that lacks p53 expression, showed no p53-mediated expression of the reporters. To further confirm specificity of the assay, we analysed p53-mediated activation in NIH3T3 cells, expressing wild-type p53, as well as in p53-nullizygous 10-1 (Harvey and Levine, 1991) and SW480 that carry p53 inactivated by missense mutations (Abarzua et al., 1995) . As shown in Figure 3 , no p53-dependent activity was detected in 10-1 or SW480 cell lines, whereas high levels of CAT activity were observed in NIH3T3 fibroblasts. Although transient transfections per ser may cause induction of p53 and transactivation of reporters (Renzing and Lane, 1995) , elevated steadystate levels of p21
Waf1 argue in favor of the presence of a constitutively active endogenous p53. The apparent lack of correlation between the amounts of wild-type p53 and its transactivation activity is not surprising in the view of multiple post-translational modifications and cofactor proteins that modulate p53 function (reviewed in Vogelstein et al. (2000) ).
Failure of the tumor suppressor function may indicate the lack or deregulation of an essential cofactor(s) of (1998) ). p16 is a cdk inhibitor, while p14
ARF is a regulator of p53. To check if our cell lines retained p16 and p14 ARF transcripts, their relative levels were assayed by RT-PCR as reported previously (Tannapfel et al., 2001) (Figure 2b ). We found that the presence of wild-type p53 correlated with complete loss (UISO-MEL-7, 8, and 16) or significant reduction (UISO-MEL-29) of p16 and p14 ARF expression, while mutations in p53 (UISO-MEL-11 and 23) coexisted with much higher levels of both transcripts. Interestingly, the p53-deficient line UISO-MEL-6 has lost p16, but not p14 ARF expression. This is in line with previous reports of selective inactivation of p16, but not p14 ARF in familial melanomas (Hussussian et al., 1994) . The inverse correlation between p14 ARF and p53 status may indicate that both are components of the same pathway, which could be interrupted at either step. However, these Figure 1 Structural analysis of p53 in human melanoma cell lines. Total RNA extracted from cells using Trizol reagent (Invitrogen) was subjected to reverse transcription (Superscript II, Invitrogen) using oligo dT primers (Invitrogen). Full-length p53 fragment was obtained by subsequent PCR with p53S (TTC CAC GAC GGT GAC ACG CT) and p53AS1 (CTT CTG ACG CAC ACC TAT TG) primers using Adv-HF2 PCR kit (Clontech). The resulted fragment was sequenced with p53S, p53AS1 or an internal p53AS5 (GAG TTC CAA GGC CTC ATT CA) primer. Full-length p21 fragment was made by PCR with p21S (ATA TGT TAA CAT GTC AGA ACC GGC TGG GGA TG) and p21AS (CAT TGG ATC CGA TTA GGG CTT CCT CTT GGA GA) primers and sequenced using the same primers. All sequencing was performed in the Sequencing Facility of the Cleveland Clinic Foundation. UISO-MEL-3, 7, 8, 11, 16, 23 and 29 and UISO-CMN-1 were maintained in minimal essential medium with Hanks' salts (MEM-H, Gibco BRL) supplemented with 10% of fetal bovine serum (FBS, Atlanta Biochemicals), sodium bicarbonate, penicillin and streptomycin. UISO-MEL-6 and human fibroblasts WS1 were grown in minimal essential medium with Earle's salts (MEM-E, Gibco BRL) containing 10% of heat-inactivated FBS, 2 mm lglutamine, nonessential amino acids, penicillin and streptomycin. (a) Western blot analyses of p53, p21, p33 ING1b and p24 ING1c was performed essentially as described in Salti et al. (2001) using antip53 DO-1 (Ab-6, Oncogene Science), which recognizes both wildtype and mutant p53, and anti-p21 EA10 (Ab-1, Oncogene Science), while p33
ING1b and p24 ING1c were detected with previously described anti-ING1 monoclonal antibody (Garkavtsev et al., 1997) . To assure equal amounts of protein loaded, the membrane was stained with Ponceau (Sigma). (c,d) Levels of p53 and p21 proteins in melanoma cells upon gamma-irradiation. UISO-MEL-7 (c) or UISO-MEL-29 (d) were irradiated with 15 Gy using a 137 Cs g-source at a dose rate of 3.85 Gy/min and harvested 8, 16, 24, 48 and 72 h later and assayed for p53 and p21 levels by Western blot analysis as described (Salti et al., 2001) . (b) Levels of p16, p14 ARF and Apaf-1 transcripts. Relative amounts of transcripts were estimated by semiquantitative RT-PCR. In total, 2 mg of total RNA was reverse transcribed (Superscript II, Invitrogen) using oligo dT (Invitrogen) primers and subjected to subsequent PCR. Fragments corresponding to p16 and p14 ARF were amplified for 35 cycles as described previously (Tannapfel et al., 2001) . Apaf-1 expression was assayed by PCR for 30 cycles using two sets of primers: HAP1s1 (GGT CAA GTG ACT GCT TCC TC) and HAP1as1 (ACC ATC AGC AGA CCA CGA AC) that a produce a 274 bp fragment spanning the region between exons 15 and 17 of Apaf-1 transcript, and primers HAP1s2 (CTG CTG TTG CTT AAG TCC AC) and HAP1as2 (TTC CTG ATG GCC TCG TAG AA) that amplify 240 bp fragment between exons 21 and 23. Amounts of GAPDH transcripts were measured under the same conditions for 25 cycles using primers GGC TCT CCA GAA CAT CAT CCC TGC and GGG TGT CGC TGT TGA AGT CAG AGG (Rauth and Davidson, 1993) . Typically, transfections were permormed two to five times with various amounts of reporter constructs. PG 13 -CAT contains CAT under control of p53-responsive elements that are mutated in reference plasmid MG 15 -CAT (Kern et al., 1991) . PG 13 -CAT and MG 15 -CAT were kindly provided by Dr B Vogelstein (Baltimore, MD, USA). Reporter construct p21-CAT carries the CAT gene under the control of p53-responsive element from the promoter of the p21 gene while control vector pTK0-CAT is devoid of p53-binding site (Garkavtsev et al., 1998) . p21-CAT and pTK0-CAT were obtained from Dr P Chumakov (Lerner Research Institute, Cleveland Clinic). Relative CAT activity represents ratio of activities of PG 13 -CAT plasmid versus control vector MG 15 -CAT (a) or p21-CAT versus control vector TK0-CAT (b) upon transient transfections in melanoma cell lines (dark bars) or mouse fibroblasts NIH3T3, 10(1) and human colon carcinoma SW480 (open bars). pIRVNeoGal plasmid was cotransfected in all cases to permit normalization for the transfection efficiency. CAT and bgalactosidase activities were determined as described previously (Kichina et al., 1996) p53 in melanoma JV Kichina et al observations suggest that the view of p14 ARF as simply an indirect regulator of p53 stability (Pomerantz et al., 1998) may not be entirely accurate, since p53 levels remained elevated despite reduced p14 ARF expression. Candidate tumor suppressor gene ING1 was reported to modulate p53 stability and function (Garkavtsev et al., 1998; Leung et al., 2002) : overexpression of its short protein product, p24
ING1c cooperated with p53 in transcriptional activation, while the longer product, p33
ING1b was found to have an opposite effect (Zeremski et al., 1999) . ING1 was found recently to be frequently upregulated in melanomas (Campos et al., 2002; Nouman et al., 2002) . Unfortunately, previous reports either did not discriminate among different isoforms or focused exclusively on one of them, p33
ING1b . To check whether alterations in ING1 expression could contribute either to elevated expression or to reduced toxicity of p53 in melanoma cells, we determined the levels of endogenous p33
ING1b and p24 ING1c in melanoma cell lines in comparison with benign nevus-derived UISO-CMN-1 cells (Figure 2a ). Most melanoma lines showed uniformly elevated levels of p33
ING1b and p24 ING1c proteins regardless of p53 status. This is in agreement with prior reports that expression of ING1 is p53-independent (Cheung et al., 2000) . To see if further overexpression of either ING1 isoform could restore cytotoxic or cytostatic functions of p53, we performed a clonogenic assay upon transduction of melanoma cells with retroviral constructs expressing p33
ING1b or p24 ING1c proteins using an insert-free vector as a control. No differences in colony numbers were observed among the three retroviral constructs in any of the cell lines tested (data not shown) indicating no restoration of growth inhibitory function of p53 by misbalanced expression of ING1-encoded proteins. We cannot exclude, however, that intrinsically high levels of ING1 contribute to the stabilization of p53 in melanoma through interference with MDM2 as reported by Leung et al. (2002) .
The tolerance towards high levels of endogenous wildtype p53 may indicate that melanomas have lost some essential downstream components of this signaling pathway. If this is the case, one may predict that such cells would remain insensitive to ectopic expression of p53 as well. To test this assumption, we analysed colony formation upon retrovirus-mediated p53 gene transfer. All cell lines except for UISO-MEL-7 demonstrated a significant reduction in the number of colonies upon infection with pPSNeo-p53
WT (Garkavtsev et al., 1998) , which encodes human wild-type p53, as compared to the infections with an insert-free pPSNeo or pPSNeop53175
His , which carries cDNA for a dominant-negative p53 mutant (Figure 4a ). In contrast, UISO-MEL-7 appeared to be resistant to ectopical overexpression of wild-type p53. Our results are in agreement with previous work (Cirielli et al., 1995) , which showed that transduction with adenovirus encoding wild-type p53 could increase cell death and apoptotic index in the SK-MEL-24 cell line in vivo and in vitro. Essentially the same results were obtained with another set of retroviral constructs prepared on the basis of retroviral vector pLXSN (Figure 4b) . Notably, although we have not Figure 4 Retroviral transfer of p53 in melanoma cells. Infectious retrovirus was produced by transfecting A293-based amphotropic packaging cell line (Clontech) with retroviral constructs as described (Pear et al., 1993) . At 24 and 48 h after transfection retrovirus containing medium was collected and used to infect target cells in the presence of 4-mg/ml of polybrene (Sigma). At 24 h after transduction infectants were subjected to selection with 0.5 mg/ml of G418 (Gibco-BRL). (a) Colony formation upon transduction of retroviral vectors pPSNeo (empty vector), pPSNeo-p53 WT (wild-type p53) or pPSNeo-p53 175His (mutant p53) (Garkavtsev et al., 1998) provided by Dr P Chumakov (Lerner Research Institute, Cleveland Clinic). Following G418 selection, colonies were stained with 2% crystal violet (Sigma) dissolved in 10% methanol. Representative wild-type p53-sensitive UISO-MEL-6, and 11 cell lines and wild-type p53-resistant UISO-MEL-7 are shown. Number of colony forming units per milli liter of retrovirus containing medium was estimated by titration on Rat1a cells that are resistant to the ectopical overexpression of wildtype p53. (b) Number of colonies obtained upon transduction with pLp53SN relative to the control vector pLXSN. (c) Levels of p53 and p21 proteins in UISO-MEL-7 pooled transductants as determined by Western blotting performed as in Salti et al. (2001) detected a correlation between p53 amounts and sensitivity to infection with a p53-encoding virus, the growth inhibitory effect of exogenous p53 was more pronounced in p53-deficient cell lines.
Overexpression of p53 in wild-type p53 transductants UISO-MEL-7 was confirmed by Western blotting. The highest amounts of p53 were detected in UISO-MEL-7 cells transduced with pPSNeo-p53 175His (Figure 4c , lane 3) reflecting elevated stability of the 175
His mutant (Blagosklonny, 2000) . In order to test whether the p53 transgene remained functional upon transfer into UISO-MEL-7, we assessed levels of endogenous p21 Waf1 in UISO-MEL-7 are indeed p53-dependent. This is in agreement with our observation that, upon activation of p53 by DNA damage, UISO-MEL-7 cells show at least as much increase in p21
Waf1 levels as is seen in a p53-sensitive cell line UISO-MEL-29 (Figure 2c and  d) . Moreover, sequencing analysis of p21 cDNA showed that endogenous p21 in UISO-MEL-7 is wild type.
It was previously suggested by Soengas et al. (2001) that melanomas could become resistant to p53-dependent apoptosis due to loss or reduction in the expression of APAF-1 transcripts. To determine if this could account for the observed resistance to p53 in UISO-MEL-7 and for reduced sensitivity to endogenous wildtype p53 in other melanoma cell lines, we analysed the relative levels of Apaf-1 transcripts in melanoma as well as in benign cells (Figure 2b) . We found that all melanoma lines expressed Apaf-1 at levels comparable to those of benign UISO-CMN-1 even though UISO-MEL-6 and 23 had slightly higher levels of the expression. These findings weigh against the involvement of APAF-1 loss in the observed resistance to wildtype p53.
Overall, we concluded that melanoma's tolerance to p53 is limited to certain levels of expression of this tumor suppressor. The p53 pathway in melanomas, retaining wild-type p53, is not completely repressed but only attenuated by some unknown factor(s). Identification of these factors, which are likely to be prospective drug targets, should be an important step towards development of new rational approaches to melanoma treatment. Our observations indicate that p14ARF, whose status is inversely correlated to that of p53, could be one of these factors. Additional research, however, is needed to confirm this hypothesis.
